Literature DB >> 34609678

Low eGFR and albuminuria independently predict all-cause mortality in high-risk subjects undergoing coronary arteriography.

Maria Maddalena D'Errico1, Pamela Piscitelli1, Antonio Mirijello1, Mariateresa Santoliquido1,2, Valentina Massa1, Mauro Salvatori3, Carlo Vigna3, Gianluigi Vendemiale4, Filippo Aucella5, Roberto Pontremoli6, Salvatore A De Cosmo7.   

Abstract

Individuals with Chronic Kidney Disease (CKD) are at high risk for cardiovascular morbidity and mortality. The aim of this study was to examine the relationship between renal dysfunction and all-cause mortality in a sample of subjects undergoing coronary angiography (CA). We evaluated 1017 subjects who consecutively underwent CA. Glomerular filtration rate (eGFR) was estimated by CKD-EPI and urinary albumin excretion reported as urinary albumin-to-creatinine ratio. Vital status was ascertained by interrogating the Italian Health Card Database. One-thousand-seventeen subjects (759 M/258F) were enrolled into the study from 2016 to 2018. One-hundred-fourteen deaths occurred during a median follow-up of 44 months. The whole population was divided in two subgroups according to the presence/absence of low eGFR (i.e. < 60 ml/min/1.73 m2). Subjects with low baseline eGFR had a worse clinical profile than subjects with preserved kidney function. The risk of death in subjects with eGFR < 60 ml/min/1.73 m2 was almost three times higher than in subjects with preserved kidney function: fully adjusted HR 2.70 (95% CI 1.56-4.67). The presence of albuminuria also predicted a high risk of death: fully adjusted HR 2.09 (95% CI 1.17-3.73) and HR 4.26 (95% CI 2.18-8.33), microalbuminuria or macroalbuminuria, respectively, being normoalbuminuria the reference group. Again, the increased risk remained significant after adjusting for several potential confounders. In conclusion, kidney disease measures (i.e. low eGFR or albuminuria) independently predict increased risk for all-cause death in a large sample of subjects undergoing CA. These results have a relevant clinical impact.
© 2021. Società Italiana di Medicina Interna (SIMI).

Entities:  

Keywords:  Albuminuria; Cardiovascular risk; Coronary artery disease; GFR; Mortality

Mesh:

Substances:

Year:  2021        PMID: 34609678     DOI: 10.1007/s11739-021-02851-4

Source DB:  PubMed          Journal:  Intern Emerg Med        ISSN: 1828-0447            Impact factor:   3.397


  22 in total

1.  Kidney disease measures are associated with the burden of coronary atherosclerosis, independently of diabetes.

Authors:  Maria Maddalena D'Errico; Antonio Mangiacotti; Daniele Graziano; Valentina Massa; Pamela Piscitelli; Gianluigi Vendemiale; Francesca Viazzi; Roberto Pontremoli; Aldo Russo; Nicola Marchese; Carlo Vigna; Salvatore De Cosmo
Journal:  Acta Diabetol       Date:  2017-07-21       Impact factor: 4.280

2.  Increased urinary albumin excretion, insulin resistance, and related cardiovascular risk factors in patients with type 2 diabetes: evidence of a sex-specific association.

Authors:  Salvatore De Cosmo; Antonio Minenna; Oznelle Ludovico; Sandra Mastroianno; Anna Di Giorgio; Leonardo Pirro; Vincenzo Trischitta
Journal:  Diabetes Care       Date:  2005-04       Impact factor: 19.112

3.  Cause of Death in Patients with Reduced Kidney Function.

Authors:  Stephanie Thompson; Matthew James; Natasha Wiebe; Brenda Hemmelgarn; Braden Manns; Scott Klarenbach; Marcello Tonelli
Journal:  J Am Soc Nephrol       Date:  2015-03-02       Impact factor: 10.121

4.  Prognostic Value of Albuminuria on Cardiovascular Outcomes After Elective Percutaneous Coronary Intervention.

Authors:  Ayako Kunimura; Hideki Ishii; Tadayuki Uetani; Ken Harada; Takashi Kataoka; Masahiro Takeshita; Kazuhiro Harada; Satoshi Okumura; Norihiro Shinoda; Bunichi Kato; Masataka Kato; Susumu Suzuki; Tetsuya Amano; Toyoaki Murohara
Journal:  Am J Cardiol       Date:  2015-12-12       Impact factor: 2.778

5.  Reduced glomerular filtration rate and prior cardiovascular event entail similar risk for coronary atherosclerotic burden.

Authors:  P Piscitelli; A Mangiacotti; N Marchese; E V Greco; M M D'Errico; V Massa; A Mirijello; A P Palena; G Vendemiale; A Russo; C Vigna; F Aucella; R Pontremoli; S De Cosmo
Journal:  Eur Rev Med Pharmacol Sci       Date:  2020-09       Impact factor: 3.507

Review 6.  Chronic kidney disease: global dimension and perspectives.

Authors:  Vivekanand Jha; Guillermo Garcia-Garcia; Kunitoshi Iseki; Zuo Li; Saraladevi Naicker; Brett Plattner; Rajiv Saran; Angela Yee-Moon Wang; Chih-Wei Yang
Journal:  Lancet       Date:  2013-05-31       Impact factor: 79.321

Review 7.  Chronic kidney disease and cardiovascular risk: epidemiology, mechanisms, and prevention.

Authors:  Ron T Gansevoort; Ricardo Correa-Rotter; Brenda R Hemmelgarn; Tazeen H Jafar; Hiddo J Lambers Heerspink; Johannes F Mann; Kunihiro Matsushita; Chi Pang Wen
Journal:  Lancet       Date:  2013-05-31       Impact factor: 79.321

8.  A new equation to estimate glomerular filtration rate.

Authors:  Andrew S Levey; Lesley A Stevens; Christopher H Schmid; Yaping Lucy Zhang; Alejandro F Castro; Harold I Feldman; John W Kusek; Paul Eggers; Frederick Van Lente; Tom Greene; Josef Coresh
Journal:  Ann Intern Med       Date:  2009-05-05       Impact factor: 25.391

Review 9.  Kidney disease as a risk factor for development of cardiovascular disease: a statement from the American Heart Association Councils on Kidney in Cardiovascular Disease, High Blood Pressure Research, Clinical Cardiology, and Epidemiology and Prevention.

Authors:  Mark J Sarnak; Andrew S Levey; Anton C Schoolwerth; Josef Coresh; Bruce Culleton; L Lee Hamm; Peter A McCullough; Bertram L Kasiske; Ellie Kelepouris; Michael J Klag; Patrick Parfrey; Marc Pfeffer; Leopoldo Raij; David J Spinosa; Peter W Wilson
Journal:  Circulation       Date:  2003-10-28       Impact factor: 29.690

Review 10.  Global Prevalence of Chronic Kidney Disease - A Systematic Review and Meta-Analysis.

Authors:  Nathan R Hill; Samuel T Fatoba; Jason L Oke; Jennifer A Hirst; Christopher A O'Callaghan; Daniel S Lasserson; F D Richard Hobbs
Journal:  PLoS One       Date:  2016-07-06       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.